SS-31 (Elamipretide)
Mitochondria-targeting peptide investigated clinically; the pivotal phase 3 MMPOWER-3 trial did not meet its primary endpoints in the overall PMM population.
Stacks containing SS-31 (Elamipretide)
Public community stacks that include this ingredient.
Mitochondria-oriented peptide grouping. SS-31 has clinical trials in specific mitochondrial diseases; MOTS-C is mostly preclinical.
MMPOWER-3 found no significant improvement in 6-minute walk test distance or fatigue scores with 40 mg/day subcutaneous elamipretide vs. placebo over 24 weeks in the overall PMM population (Class I evidence of no benefit on primary endpoints). A post-hoc subgroup analysis suggested possible benefit in patients with nuclear DNA variants. Elamipretide was well-tolerated.
An earlier short-course dose-escalation study reported improved exercise performance after 5 days; the larger phase 3 MMPOWER-3 trial did not confirm sustained benefit on primary endpoints.